The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets
Abstract
The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell mass, and inhibit beta-cell apoptosis in animal models of diabetes. The aim of the present study was to evaluate whether GLP-1 could improve function and inhibit apoptosis in freshly isolated human islets. Human islets were cultured for 5 d in the presence, or absence, of GLP-1 (10 nm, added every 12 h) and studied for viability and expression of proapoptotic (caspase-3) and antiapoptotic factors (bcl-2) as well as glucose-dependent insulin production. We observed better-preserved three-dimensional islet morphology in the GLP-1-treated islets, compared with controls. Nuclear condensation, a feature of cell apoptosis, was inhibited by GLP-1. The reduction in the number of apoptotic cells in GLP-1-treated islets was particularly evident at d 3 (6.1% apoptotic nuclei in treated cultures vs. 15.5% in controls; P < 0.01) and at d 5 (8.9 vs. 18.9%; P < 0.01). The antiapoptotic effect of GLP-1 was associated with the down-regulation of active caspase-3 (P < 0.001) and the up-regulation of bcl-2 (P < 0.01). The effect of GLP-1 on the intracellular levels of bcl-2 and caspase-3 was observed at the mRNA and protein levels. Intracellular insulin content was markedly enhanced in islets cultured with GLP-1 vs. control (P < 0.001, at d 5), and there was a parallel GLP-1-dependent potentiation of glucose-dependent insulin secretion (P < 0.01 at d 3; P < 0.05 at d 5). Our findings provide evidence that GLP-1 added to freshly isolated human islets preserves morphology and function and inhibits cell apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 2×
“It has been demonstrated that the role of GLP-1 extends beyond its glucose-lowering action in response to food ingestion and included the de novo synthesis of proinsulin (2).”
BackgroundGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502
Self-citationGlucagon-Like Peptides: Regulators of Cell Proliferation, Differentiation, and Apoptosis
Drucker, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0306 · Cited by 484
Perfetti, R., Zhou, J., Doyle, M. E., & Egan, J. M. (2000) · Endocrinology · doi:10.1210/endo.141.12.7806 · Cited by 448
Self-citationButeau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411
In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system
Srinivasan, A. N., Roth, K. A., Sayers, R. O., Shindler, K. S., Wong, A., Fritz, L. C., & Tomaselli, K. J. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400449 · Cited by 368
Tourrel‐Cuzin, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 365
Zhou, J., Wang, X., Piñeyro, M. A., & Egan, J. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Abraham, E. J., Leech, C. A., Lin, J. C., Zulewski, H., & Habener, J. F. (2002) · Endocrinology · doi:10.1210/endo.143.8.8973 · Cited by 310
Improved Human Islet Isolation Using a New Enzyme Blend, Liberase
Linetsky, E., Bottino, R., Lehmann, R., Alejandro, R., Inverardi, L., & Ricordi, C. (1997) · Diabetes · doi:10.2337/diab.46.7.1120 · Cited by 309
Hui, H., Nourparvar, A., Zhao, X., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2002-220897 · Cited by 307
Self-citationTourrel‐Cuzin, C., Bailbé, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 292
Rolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 282
Buteau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252
Regulation of beta-cell mass by hormones and growth factors.
Nielsen, J. H., Galsgaard, E. D., Møldrup, A., Friedrichsen, B. N., Billestrup, N., Hansen, J. A., Lee, Y., & Carlsson, C. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s25 · Cited by 238
Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy
León, D. D. D., Deng, S., Madani, R., Ahima, R. S., Drucker, D. J., & Stoffers, D. A. (2003) · Diabetes · doi:10.2337/diabetes.52.2.365 · Cited by 173
Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose‐Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172
Self-citationGarcı́a-Ocaña, A., Vasavada, R. C., Cebrián, A., Reddy, V. T., Takane, K. K., López-Talavera, J. C., & Stewart, A. F. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2752 · Cited by 160
Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1
Holst, J. J. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.328 · Cited by 156
Glucagon-like peptide 1 (1–37) converts intestinal epithelial cells into insulin-producing cells
Suzuki, A., Nakauchi, H., & Taniguchi, H. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0936260100 · Cited by 140
β-Cell Differentiation from a Human Pancreatic Cell Line in Vitro and in Vivo
de la Tour, D. D., Halvorsen, T., Demeterco, C., Tyrberg, B., Itkin‐Ansari, P., Loy, M., Yoo, S.-J., Hao, E., Bossie, S., & Levine, F. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.3.0604 · Cited by 129
Nauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113
IGF-I and GH post-receptor signaling mechanisms for pancreatic beta-cell replication
Rhodes, C. J. (2000) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0240303 · Cited by 93
Factors controlling pancreatic cell differentiation and function
Edlund, H. (2001) · Diabetologia · doi:10.1007/s001250100623 · Cited by 84
Functional Maturation of Fetal Porcine β-Cells by Glucagon-Like Peptide 1 and Cholecystokinin
Hardikar, A. A., Wang, X. Y., Williams, L. J., Kwok, J. C., Wong, R., Yao, M., & Tuch, B. E. (2002) · Endocrinology · doi:10.1210/en.2001-211344 · Cited by 81
Using β-Cell Growth Factors to Enhance Human Pancreatic Islet Transplantation*
Garcı́a-Ocaña, A., Vasavada, R. C., Takane, K. K., Cebrián, A., López-Talavera, J. C., & Stewart, A. F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7315 · Cited by 63
Gahr, S., Merger, M., Bollheimer, L., Hammerschmied, C., Schölmerich, J., & Hügl, S. (2002) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0280099 · Cited by 49
López-Ávalos, M. D., Tatarkiewicz, K., Sharma, A., Bonner‐Weir, S., & Weir, G. C. (2001) · Transplantation · doi:10.1097/00007890-200104270-00024 · Cited by 29
Islet transplantation as a treatment for diabetes.
Gc, W., & Bonner‐Weir, S. (1998) · PubMed · Cited by 29
Hussain, M. A., & Habener, J. F. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3198 · Cited by 26
Yamaoka, T., Yoshino, K., Yamada, T., Yano, M., Matsui, T., Yamaguchi, T., Moritani, M., Hata, J., Noji, S., & Itakura, M. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6601 · Cited by 24
Flagged first, then by citations
Cited by
Sorted by citations
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
“Most recently, GLP-1 has been shown to be capable of inhibiting apoptosis of beta cells including human beta cells (30, 65).”
BackgroundDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
“In vivo studies in rodents (296,297) and in vitro studies with cultured human islets (298) have shown that exenatide can expand -cell mass and prevent apoptosis of islets, respectively.”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Metadata
- Authors
- Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R.
- Affiliations
- Cedars-Sinai Medical Center (US)
- National Institutes of Health (US)
- Corresponding author
- Perfetti, Riccardo
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-12
- Volume
- 144
- Issue
- 12
- Pages
- 5149-5158
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2146333376
- Cited by
- 664
- References
- 34
- Citations by year
- 2026: 6 · 2025: 14 · 2024: 12 · 2023: 11 · 2022: 14 · 2021: 24 · 2020: 15 · 2019: 26 · 2018: 26 · 2017: 23 · 2016: 32 · 2015: 28 · 2014: 36 · 2013: 50 · 2012: 40
- FWCI
- 23.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, beta-cell apoptosis, human pancreatic islets, glucose-dependent insulin secretion, caspase-3, Bcl-2, islet viability, islet morphology, insulin content, islet transplantation, diabetes mellitus
- MeSH terms
- Insulin Secretion, Cell Survival, Cells, Cultured, Fluorescent Antibody Technique, Fluorescent Dyes, Glucagon, Glucose, Humans, Indoles, Insulin, Islets of Langerhans, Peptide Fragments, Protein Precursors, RNA, Messenger, Gene Expression, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Reverse Transcriptase Polymerase Chain Reaction, Caspases, Glucagon-Like Peptide 1, Caspase 3, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review